Compare TPH & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPH | CRNX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 2012 | 2018 |
| Metric | TPH | CRNX |
|---|---|---|
| Price | $46.69 | $34.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $42.50 | ★ $74.78 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $3,260,447,000.00 | $1,039,000.00 |
| Revenue This Year | N/A | $722.66 |
| Revenue Next Year | $10.20 | $183.79 |
| P/E Ratio | $17.17 | ★ N/A |
| Revenue Growth | ★ 5.76 | N/A |
| 52 Week Low | $27.90 | $24.10 |
| 52 Week High | $46.76 | $57.99 |
| Indicator | TPH | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 79.62 | 32.87 |
| Support Level | $46.24 | $33.23 |
| Resistance Level | $46.76 | $37.23 |
| Average True Range (ATR) | 0.11 | 1.60 |
| MACD | -0.34 | 0.13 |
| Stochastic Oscillator | 83.52 | 23.01 |
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. Its financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.